The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials.

about

The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials.

Item

http://www.wikidata.org/entity/Q38268544

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

The pharmacological costs of c ...... ished Phase II and III trials.

@en

type

Item

label

The pharmacological costs of c ...... ished Phase II and III trials.

@en

prefLabel

The pharmacological costs of c ...... ished Phase II and III trials.

@en

P1476

The pharmacological costs of c ...... ished Phase II and III trials.

@en

P2093

Anna Mercanti

http://www.w3.org/2001/XMLSchema#string

Anna Rita Trolese

http://www.w3.org/2001/XMLSchema#string

Emilia Durante

http://www.w3.org/2001/XMLSchema#string

Filippo Greco

http://www.w3.org/2001/XMLSchema#string

Michele Tognetto

http://www.w3.org/2001/XMLSchema#string

Paolo Piacentini

http://www.w3.org/2001/XMLSchema#string

Silvia Muraro

http://www.w3.org/2001/XMLSchema#string

P2860

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

Bending the Cost Curve in Cancer Care

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

The number needed to treat: a clinically useful measure of treatment effect

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

P304

101-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737167.2015.982099

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Bonetti

Jacopo Giuliani

P577

2014-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25399933

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

phase II clinical trial